MorphoSys May Be One To Watch at J.P. Morgan

14 Dec 2023

Excitement continues to grow around pelabresib after the presentation of promising data for the German group’s myelofibrosis drug.

Morphosys ASH — The Morphosys booth at ASH • Source: Alaric DeArment

MorphoSys AG may not have added much more detail about its closely-watched myelofibrosis candidate pelabresib at the American Society of Hematology meeting but as the doors closed at the San Diego congress, the consensus was that the German biotech is well placed to get approval for one of the sector’s most valuable late-stage assets.

Ahead of ASH, the Munich-based group had presented topline results from the Phase III MANIFEST-2 trial of pelabresib, an investigational...